Sinclair's Life Bio Reports First Human Data for ER-100: Early Vision Signals in 2 of 3 Glaucoma Patients

What was announced

On October 8, Sinclair-cofounded Life Biosciences released the first interim human data from its Phase 1 trial of ER-100, a gene therapy that delivers three reprogramming factors (OCT4, SOX2 and KLF4) to partially reprogram cells. The data covers three participants with open-angle glaucoma, who received a single intravitreal injection at the lowest dose followed by eight weeks of oral doxycycline to switch the genes on.

Safety and early signals

The company reports ER-100 was well tolerated through Day 56, with no dose-limiting toxicities or serious adverse events. It attributes the adverse events that did occur to the injection procedure, the prednisolone taper, or pre-existing conditions. On visual-field testing, two of the three participants improved: in each, at least 28% of tested points gained more than 4 dB. The Data Safety Monitoring Board has recommended escalating to a roughly threefold higher dose.

Caveats and criticism

The sample is three people, with no control group and only eight weeks of follow-up. The trial was designed mainly to assess safety, so the vision results are preliminary signals. The 28% figure refers to the share of test locations that improved, not an overall 28% gain in vision. The data also do not show that cells were made biologically younger, and the results come from a company press release rather than peer review. No data were reported for NAION, the other target indication.

What comes next

The trial continues at the higher dose level, and larger controlled studies would be needed to show whether any benefit is real and durable. For now, this is the first human look at partial epigenetic reprogramming: an encouraging early step, not proof of age reversal.